natgillin/translations-raw huggingface dataset:
The rate (95% confidence interval) of non-melanoma skin cancers was 8.8 (6.0, 13.0) per 1,000 patient-years among Humira-treated patients and 3.2 (1.3, 7.6) per 1,000 patient-years among control patients.
Delež (95 % interval zaupanja) nemelanomskih kožnih rakov je bil 8,8 (6,0; 13,0) na 1000 bolnikovlet med bolniki, ki so dobivali zdravilo Humira, in 3,2 (1,3; 7,6) na 1000 bolnikov-let med kontrolnimi bolniki.
In patients with psoriatic arthritis, anti-adalimumab antibodies were identified in 38/376 subjects (10%) treated with adalimumab.
Med bolniki s psoriatičnim artritisom so protitelesa proti adalimumabu ugotovili pri 38/376 (10 %) tistih, ki so dobivali adalimumab.
Rheumatoid arthritis Age or body weight
Revmatoidni artritis Starost ali telesna masa
Plaque psoriasis is a skin condition that causes red, flaky, crusty patches of skin covered with silvery scales.
Luskavica v plakih je bolezen kože, pri kateri nastajajo rdeče, kosmičaste, krastave lise na koži, pokrite s srebrnimi luskami.
• Your child's belly (abdomen) at least 5 cm from his/her belly button (navel)
• na trebuhu vašega otroka; najmanj 5 cm oddaljeno od popka
• Using your thumb or a piece of gauze, apply pressure over the injection site for 10 seconds.
• S palcem ali koščkom gaze 10 sekund pritiskajte na injekcijsko mesto.
Do not remove the needle cover until just before injection.
Pokrovček igle odstranite šele tik pred injiciranjem.
Pulmonary fibrosis
pljučna fibroza1)
Tell your doctor immediately if you experience symptoms like changes in your vision, weakness in your arms or legs or numbness or tingling in any part of your body.
Zdravniku takoj povejte, če se pri vas pojavijo simptomi, kot so spremembe vida, šibkost rok ali nog ali pa odrevenelost ali mravljinčenje v katerem koli delu telesa.
In subjects treated with Humira with no radiographic progression from baseline to Week 48 (n=102), 84% continued to show no radiographic progression through 144 weeks of treatment.
Pri 84 % preiskovancev, ki so dobivali zdravilo Humira in od izhodišča do 48. tedna niso imeli rentgenografsko vidnega napredovanja (n = 102), se takšno napredovanje tudi do 144. tedna zdravljenja ni pojavilo.
• intestinal infections (including gastroenteritis)
• črevesne okužbe (vključno z gastroenteritisom)
• cancer that affects the lymph system
• rak, ki zajame limfni sistem
If the remaining volume is less than the prescribed dose volume, DO NOT use the syringe and contact your healthcare provider.
Če je preostala količina manjša od količine predpisanega odmerka, brizge, NE
Patients with at least a partial response to Humira 40 mg weekly after 12 weeks of treatment.
36. teden a Bolniki z vsaj delnim odzivom na odmerek 40 mg Humira po 12. tednih zdravljenja.
The posology of Humira in these patients has been determined from pharmacokinetic modelling and simulation (see section 5.2).
Kliničnih študij z zdravilom Humira pri mladostnikih s HS ni. Odmerjanje zdravila Humira pri teh bolnikih je bilo določeno na podlagi farmakokinetičnega modeliranja in simulacije (glejte poglavje 5.2).
In patients with polyarticular juvenile idiopathic arthritis who were 2 to < 4 years old or aged 4 and above weighing <15 kg, anti-adalimumab antibodies were identified in 7% (1/15) of patients, and the one patient was receiving concomitant methotrexate.
Med bolniki s poliartikularnim juvenilnim idiopatskim artritisom, ki so bili stari od 2 do < 4 let ali 4 leta in več in so tehtali <15 kg, so protitelesa proti adalimumabu ugotovili pri 7 % (1/15) bolnikov, en bolnik je sočasno prejemal metotreksat.
>32 weeks
> 32 tednov 20 tednov
Humira is administered every other week via subcutaneous injection.
Zdravilo Humira se odmerja vsak drugi teden v obliki subkutane injekcije.
• Do not recycle or throw the pre-filled syringe in the household waste
• Uporabljene napolnjene injekcijske brizge ne reciklirajte ali zavrzite med gospodinjske odpadke.
At Week 52, 42.9% of patients who received Humira/methotrexate combination therapy achieved clinical remission (DAS28 (CRP) < 2.6) compared to 20.6% of patients receiving methotrexate monotherapy and 23.4% of patients receiving Humira monotherapy.
Po 52. tednih je klinično remisijo (DAS28 (CRP)< 2,6) doseglo 42,9 % bolnikov, ki so dobivali kombinirano terapijo z zdravilom Humira/metotreksatom, 20,6 % bolnikov, ki so dobivali metotreksat v monoterapiji, in 23,4 % bolnikov, ki so dobivali zdravilo Humira v monoterapiji.
Fever, bruising, bleeding or looking pale
modrice, krvavitve, bledica
• acid reflux disease
• bolezen refluksa kisline
• People with more serious rheumatoid arthritis that have had the disease for a long time may have a higher than average risk of getting lymphoma (a cancer that affects the lymph system) and leukaemia (a cancer that affects the blood and bone marrow).
• Pri bolnikih z resnejšim revmatoidnim artritisom, ki imajo bolezen že dolgo, obstaja povečana verjetnost, da zbolijo za limfomom (rak, ki prizadene limfatični sistem) in levkemijo (rak, ki prizadene kri in kostni mozeg).
With automatic needle guard.
S ščitnikom za iglo.
2-sided P value from log rank test. NE = not estimable.
2-stranska vrednost p testa log-rank.
• severe rash, hives or other signs of allergic reaction
• hud izpuščaj, koprivnico ali druge znake alergijske reakcije
For patients who stayed on their randomised therapy, the mean (±SD) adalimumab trough concentrations at Week 52 were 9.5±5.6g/ml for the Standard Dose group and 3.5±2.2 g/ml for the Low Dose group.
Pri bolnikih, ki so ostali na njihovi randomizirani terapiji, so bile povprečne najmanjše koncentracije adalimumaba v 52. tednu 9,5 ± 5,6 μg/ml v skupini s standardnim odmerkom in 3,5 ± 2,2 μg/ml v skupini z majhnim odmerkom.
• hepatosplenic T-cell lymphoma (a rare blood cancer that is often fatal)
• jetrnovranični limfom celic T (redka oblika krvnega raka, ki je pogosto smrtna)
Place the white end of the pre-filled pen at a right angle (90 degrees) to the skin, so that you can see the window.
Namestite beli konec napolnjenega injekcijskega peresnika pravokotno (90 stopinj) na kožo,
c Inactive Disease Partial Flare Assessment of SpondyloArthritis international Society Baseline is defined as open label baseline when patients have active disease.
Delni zagon boleznid a ocena spondiloartritičnega mednarodnega združenja (Assessment of Spondyloarthritis International Society b izhodišče je določeno kot izhodišče odprte faze, ko imajo bolniki aktivno bolezen c ocena bolezenske aktivnosti ankilozirajočega spondilitisa (Ankylosing Spondylitis Disease
Humira is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy.
Zdravilo Humira je indicirano za zdravljenje zmerne do hude kronične psoriaze v plakih pri odraslih bolnikih, ki so kandidati za sistemsko zdravljenje.
This risk may increase if your child has problems with his/her lungs.
Tveganje je lahko večje, če ima vaš otrok okvarjeno delovanje pljuč.
Humira has been studied in rheumatoid arthritis, polyarticular juvenile idiopathic arthritis and psoriatic arthritis patients taking Humira as monotherapy and those taking concomitant methotrexate.
Zdravilo Humira so raziskali pri bolnikih z revmatoidnim artritisom, poliartikularnim juvenilnim idiopatskim artritisom in psoriatičnim artritisom, ki so zdravilo Humira jemali v monoterapiji, kot pri tistih, ki so jo jemali hkrati z metotreksatom.
• gallbladder inflammation, gallbladder stones
• vnetje žolčnika, žolčni kamni
• Using a piece of gauze, apply pressure over the injection site for 10 seconds.
• S koščkom gaze 10 sekund pritiskajte na injekcijsko mesto.
Your doctor may recommend temporary discontinuation.
Vaš zdravnik bo morda priporočil začasno prenehanje uporabe zdravila
The safety profile for patients with uveitis treated with Humira every other week was consistent with the known safety profile of Humira.
Varnostni profil za bolnike z uveitisom, ki so bili vsak drugi teden zdravljeni z zdravilom Humira, je v skladu z znanim varnostnim profilom zdravila Humira.
• a bump or open sore that doesn't heal
• bula ali odprta rana, ki se ne zaceli
• Keep pushing the pre-filled pen down firmly against the injection site until the injection is complete.
• Trdno potiskajte napolnjen injekcijski peresnik proti mestu injiciranja, dokler injiciranje ni končano.
During the controlled portions of pivotal Humira trials in adults of at least 12 weeks in duration in patients with moderately to severely active rheumatoid arthritis, ankylosing spondylitis, axial spondyloarthritis without radiographic evidence of AS, psoriatic arthritis, psoriasis, hidradenitis suppurativa, Crohn's disease, ulcerative colitis and uveitis, malignancies, other than lymphoma and non-melanoma skin cancer, were observed at a rate (95% confidence interval) of 6.8 (4.4, 10.5) per 1,000 patient-years among 5,291 Humira treated patients versus a rate of 6.3 (3.4, 11.8) per 1,000 patient-years among 3,444 control patients (median duration of treatment was 4.0 months for Humira and 3.8 months for control-treated patients).
V kontroliranih delih preskušanj, ki podpirajo vlogo za pridobitev dovoljenja za promet zdravila Humira pri odraslih, ki so trajala vsaj 12 tednov, pri bolnikih z zmerno do hudo aktivnim revmatoidnim artritisom, ankilozirajočim spondilitisom, aksialnim spondiloartritisom brez radiografskega dokaza za AS, psoriatičnim artritisom, psoriazo, hidradenitis suppurativa, Crohnovo boleznijo, ulceroznim kolitisom in uveitisom so malignome (razen limfoma in nemelanomskega kožnega raka) opažali z deležem (95 % interval zaupanja) 6,8 (4,4; 10,5) na 1000 bolnikov-let med 5291 bolniki, ki so dobivali zdravilo Humira, in 6,3 (3,4; 11,8) na 1000 bolnikov-let med 3444 kontrolnimi bolniki (pri prvih je zdravljenje mediano trajalo 4,0 meseca in pri drugih 3,8 meseca).
- infections, including tuberculosis - cancer - nervous system problems - vaccinations
- okužbe, vključno s tuberkulozo, - rak,
Myocardial infarction arrhythmia, congestive heart failure
pogosti tahikardija občasni miokardni infarkt1) aritmija kongestivno srčno popuščanje redki zastoj srca
• lung diseases causing shortness of breath (including inflammation)
• pljučna bolezen, ki povzroči kratko sapo (vključno z vnetjem)
Do not put either of the caps back on the pre-filled pen.
Ne enega ne drugega pokrovčka ne natikajte nazaj na napolnjeni injekcijski peresnik.
It is important to tell your doctor if your child has had or has a serious heart condition (see “Warnings and precautions”).
Pomembno je, da zdravniku poveste, če je vaš otrok imel ali ima resno bolezen srca (glejte "Opozorila in previdnostni ukrepi").
In controlled and open label adult and paediatric studies with Humira, serious infections (including fatal infections, which occurred rarely) have been reported, which include reports of tuberculosis (including miliary and extra-pulmonary locations) and invasive opportunistic infections (e.g. disseminated or extrapulmonary histoplasmosis, blastomycosis, coccidioidomycosis, pneumocystis, candidiasis,
V kontroliranih in odprtih študijah pri odraslih in otrocih z zdravilom Humira so poročali o resnih okužbah (vključno s smrtno nevarnimi okužbami, ki so se pojavile redko), med katerimi so bile tuberkuloza (tudi miliarna in zunajpljučna) in invazivne oportunistične okužbe (npr. diseminirana ali zunajpljučna histoplazmoza, blastomikoza, kokcidioidomikoza, pnevmocistoza, kandidaza,
Each pack contains 1, 2, 4 or 6 pre-filled syringes for patient use with 1, 2, 4 or 6 alcohol pads, respectively.
Eno pakiranje vsebuje 1, 2, 4 oz. 6 napolnjenih injekcijskih brizg za bolnikovo uporabo z 1, 2, 4 oz. 6 alkoholnimi zloženci.
Your doctor may prescribe another strength of Humira if your child needs a different dose.
Zdravnik lahko predpiše vašemu otroku drugo jakost zdravila Humira, če vaš otrok potrebuje drugačen odmerek.
Patients were randomised to receive either 24 mg/m2 body surface area (BSA) of Humira up to a maximum of 40 mg, or placebo every other week for 12 weeks.
Bolniki so bili randomizirani za prejemanje bodisi 24 mg/m2 telesne površine zdravila Humira do največjega posamičnega odmerka 40 mg ali placebo vsak drugi teden, 12 tednov.
* P < 0.05, ***P < 0.001, Humira versus placebo Among all randomised patients.
* P < 0,05, ***P < 0,001, zdravilo Humira v primerjavi s placebom a Med vsemi randomiziranimi bolniki.
Maintenance of remission and response rates are presented in Table 23.
Stopnje vzdrževanja remisije in odziva so prikazani v preglednici 23.
Do not recap.
Ne nameščajte ga nazaj.
• If new skin lesions appear during or after therapy or if existing lesions change appearance, tell your doctor.
• Če se vam med zdravljenjem ali po njem pojavijo nove spremembe na koži, ali če se vam spremeni videz obstoječih sprememb, morate to povedati zdravniku.
Patients demonstrating a Pediatric ACR 30 response at Week 16 were eligible to be randomised into the double blind (DB) phase and received either Humira 24 mg/m up to a maximum of 40 mg, or placebo every other week for an additional 32 weeks or until disease flare.
Bolniki, ki so 16. teden dosegli odziv »Pediatric ACR« 30, so bili primerni za randomizacijo v dvojno slepo fazo in so nadaljnjih 32 tednov ali do zagona bolezni vsak drugi teden dobili zdravilo Humira 24 mg/m2 (do največ 40 mg) ali placebo.
5 How to store Humira Contents of the pack and other information
5 Shranjevanje zdravila Humira Vsebina pakiranja in dodatne informacije
Humira is used to treat enthesitis-related arthritis in patients from 6 years of age.
Zdravilo Humira se uporablja za zdravljenje artritisa, povezanega z entezitisom pri bolnikih od 6. leta starosti.
Your doctor will decide if your child should receive Humira.
On se bo odločil, ali lahko vaš otrok dobiva zdravilo Humira.
Humira is used to treat children from 2 years of age with chronic non-infectious uveitis with inflammation affecting the front of the eye.
Zdravilo Humira se uporablja za zdravljenje otrok, starejših od 2 let, s kroničnim neinfekcijskim uveitisom, kjer vnetje prizadene sprednji del očesa.
In the larger AS study I with 315 patients, results showed statistically significant improvement of the signs and symptoms of ankylosing spondylitis in patients treated with Humira compared to placebo.
Rezultati obsežnejše študije pri ankilozirajočem spondilitisu I pri 315 bolnikih so pri bolnikih, ki so dobivali zdravilo Humira, pokazali statistično značilno izboljšanje znakov in simptomov ankilozirajočega spondilitisa v primerjavi s placebom.
• inflammation of the pancreas which causes severe pain in the abdomen and back
• vnetje trebušne slinavke, ki povzroča težjo bolečino v trebuhu in hrbtu
Clinical remission and clinical response (defined as reduction in PCDAI score of at least 15 points from Baseline) rates are presented in Table 16.
Stopnja klinične remisije in kliničnega odziva (definiran kot zmanjšanje vrednosti PCDAI vsaj za 15 točk od začetne vrednosti) sta predstavljena v preglednici 16.
Children and adolescents from 2 years of age weighing less than 30 kg The usual dose of Humira is 20 mg every other week with methotrexate.
Otroci in mladostniki, starejši od 2 let, ki tehtajo 30 kg ali več Običajni odmerek zdravila Humira je 40 mg vsak drugi teden z metotreksatom.
For patients who develop the signs and symptoms such as fever, malaise, weight loss, sweats, cough, dyspnoea, and/or pulmonary infiltrates or other serious systemic illness with or without concomitant shock an invasive fungal infection should be suspected and administration of Humira should be promptly discontinued.
Če se bolniku pojavijo znaki ali simptomi, kot so npr. zvišana telesna temperatura, splošno slabo počutje, hujšanje, znojenje, kašelj, dispneja in/ali pljučni infiltrati ali druge resne sistemske bolezni (s spremljajočim šokom ali brez njega), je treba posumiti na invazivno glivično okužbo.
Your doctor may prescribe another strength of Humira if you need a different dose.
Zdravnik vam lahko predpiše drugo jakost zdravila Humira, če boste potrebovali drugačen odmerek.
• reduction in blood platelets which increases risk of bleeding or bruising
• zmanjšanje števila krvnih ploščic, kar poveča tveganje krvavitev ali podplutb
Upon completion of the first 104 weeks, 497 patients enrolled in an open-label extension phase in which 40 mg of Humira was administered every other week up to 10 years.
Po zaključenih prvih 104 tednih, so 497 bolnikov vključili v odprto nadaljevalno fazo, med katero so še do 10 let dobivali 40 mg zdravila Humira vsak drugi teden.
• abnormal muscle breakdown
• brazgotinjenje • neobičajen razpad mišic
Adolescent hidradenitis suppurativa (from 12 years of age, weighing at least 30 kg)
Hidradenitis suppurativa pri mladostnikih (starejših od 12 let, ki tehtajo najmanj 30 kg)
Significant improvement of signs of inflammation as measured by hs-CRP and MRI of both Sacroiliac Joints and the Spine was maintained in Humira-treated patients through Week 156 and Week 104, respectively.
Statistično izboljšanje znakov vnetja, merjenih s C-reaktivnim proteinom z veliko občutljivostjo (hsCRP) in z magnetno resonanco (MRI) sakroiliakalnih sklepov in hrbtenice, se je ohranilo pri bolnikih, zdravljenih z zdravilom Humira, do 156. tedna oz. do 104. tedna, v tem zaporedju.
Upon completion of both studies, 383 patients enrolled in an open-label extension study, in which 40 mg Humira was administered every other week.
Po koncu obeh študij so 383 bolnikov vključili v odprto nadaljevalno študijo, med katero so bolniki dobivali 40 mg zdravilo
The safety profile for patients with HS treated with Humira weekly was consistent with the known safety profile of Humira.
Varnostni profil za bolnike s HS, ki so bili vsak teden zdravljeni z zdravilom Humira, je v skladu z znanim varnostnim profilom zdravila Humira.
Overall responses were generally better and, fewer patients developed antibodies when treated with the combination of Humira and MTX compared to Humira alone.
Celotni odzivi so bili med zdravljenjem s kombinacijo zdravila Humira in metotreksata na splošno boljši in pri manj bolnikih so se pojavila protitelesa kot med zdravljenjem samo z zdravilom Humira.
• nerve root compression (including low back pain and leg pain)
• stisnjenje živčnih korenin (vključno z bolečino v spodnjem delu hrbta in nogah)
If you do not respond well enough to these medicines, you will be given Humira to treat your rheumatoid arthritis.
Če se na ta zdravila ne odzovete dovolj dobro, boste za zdravljenje revmatoidnega artritisa dobili zdravilo Humira.
3) Injecting Humira
3) Injiciranje zdravila Humira
• cancer that affects the lymph system;
• rak, ki zajame limfni sistem;
In the open-label lead in phase (OL LI) patients were stratified into two groups, MTX (methotrexate)-treated or non-MTX-treated.
V odprti uvajalni fazi so bolnike stratificirali v dve skupini: zdravljene z metotreksatom in zdravljene brez metotreksata.
The efficacy of Humira was assessed in a randomised, double-blind, controlled study of 114 paediatric patients from 4 years of age with severe chronic plaque psoriasis (as defined by a Physician's Global Assessment (PGA) ≥ 4 or > 20% BSA involvement or > 10% BSA involvement with very thick lesions or Psoriasis Area and Severity Index (PASI) ≥ 20 or ≥ 10 with clinically relevant facial, genital, or hand/ foot involvement) who were inadequately controlled with topical therapy and heliotherapy or phototherapy.
Učinkovitost zdravila Humira je bila ocenjena v randomizirani, dvojno slepi, kontrolirani študiji, v katero je bilo vključenih 114 pediatričnih bolnikov od 4. leta starosti, s hudo kronično psoriazo v plakih (definirano z zdravnikovo globalno oceno (PGA - Physician's Global Assessment) ≥ 4 ali > 20 % zajete telesne površine ali > 10 % zajete telesne površine z zelo grobimi lezijami ali indeksom obsežnosti in izrazitosti psoriaze (PASI - Psoriasis Area and Severity Index) ≥ 20 ali ≥ 10 s klinično pomembnim zajetjem obraza, genitalij ali dlani/stopal), ki ni bila ustrezno nadzorovana s topikalnim zdravljenjem in helioterapijo ali fototerapijo.
Your doctor may tell you to stop using Humira for some time.
Vaš zdravnik vam bo morda povedal, da za nekaj časa prenehate z uporabo zdravila Humira.
Humira (N = 30)
Zdravilo Humira (n = 30)
In patients with non-radiographic axial spondyloarthritis, anti-adalimumab antibodies were identified in 8/152 subjects (5.3%) who were treated continuously with adalimumab.
Pri bolnikih z ne-radiografskim aksialnim spondiloartritisom so protitelesa proti adalimumabu odkrili pri 8/152 preiskovancev (5,3 %), ki so jih neprekinjeno zdravili z adalimumabom.
For patients who dose escalated from eow to weekly regimen, the mean (±SD) serum concentrations of adalimumab at Week 52 were 15.3±11.4 μg/ml (40/20 mg, weekly) and 6.7±3.5 μg/ml (20/10 mg, weekly).
Pri bolnikih, ki so prešli iz režima vsak drugi teden na režim vsak teden, so bile povprečne (±SD) serumske koncentracije adalimumaba v 52. tednu 15,3 ± 11,4 μg/ml (40/20 mg, tedensko) in 6,7 ± 3,5 μg/ml (20/10 mg, tedensko).
The recommended dose of Humira for adult patients with rheumatoid arthritis is 40 mg adalimumab administered every other week as a single dose via subcutaneous injection.
Priporočeni odmerek zdravila Humira za odrasle bolnike z revmatoidnim artritisom je 40 mg adalimumaba vsak drugi teden v enkratnem odmerku v subkutani injekciji.
Your child may first be given other disease-modifying medicines, such as methotrexate.
Vaš otrok bo morda najprej prejel druga imunomodulirajoča zdravila, npr. metotreksat.
Press the plum activator button and count slowly for 10 seconds.
Pritisnite na škrlaten sprožilni gumb in počasi štejte
Injecting Humira
Injiciranje zdravila Humira
Humira is indicated for the treatment of severe chronic plaque psoriasis in children and adolescents from 4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapies.
Zdravilo Humira je indicirano za zdravljenje hude kronične psoriaze v plakih pri otrocih in mladostnikih od 4. leta starosti, ki so se neustrezno odzvali na ali niso ustrezni kandidati za topikalno zdravljenje in fototerapije.
• expiry (EXP) date has passed
• je pretekel rok uporabnosti (EXP)
In an open-label extension study, for patients who dose escalated from 40 mg every other week to 40 mg weekly due to a PASI response below 50%, 26.4% (92/349) and 37.8% (132/349) of patients achieved PASI 75 response at Week 12 and 24, respectively.
V odprti podaljšani študiji je odziv PASI 75 v 12. oziroma 24. tednu doseglo 26,4 % (92/349) oziroma 37,8 % (132/349) bolnikov, ki so jim zaradi odziva PASI pod 50 % odmerek povečali s 40 mg vsak drugi teden na 40 mg vsak teden.
• Remove cap from needle syringe, being careful not to touch the needle or let it touch any surface.
• Odstranite pokrovček z igle na brizgi; pazite, da se igle pri tem ne dotaknete in da se z njo česa ne dotaknete.
5How to store Humira Contents of the pack and other information Injecting Humira
5 Shranjevanje zdravila Humira Vsebina pakiranja in dodatne informacije Injiciranje zdravila Humira
The pivotal controlled studies involved 6,089 patients receiving Humira and 3,801 patients receiving placebo or active comparator during the controlled period.
Kontrolirane študije, ki podpirajo vlogo za pridobitev dovoljenja za promet, so vključevale 6089 bolnikov, ki so med kontroliranim obdobjem dobivali zdravilo Humira, in 3801 bolnikov, ki so med tem obdobjem dobivali placebo ali primerjalno učinkovino.
With your index finger or your thumb, press the plum coloured button on top once you are ready to begin the injection (see below).
Ko ste pripravljeni na začetek injiciranja (glejte spodaj), s palcem ali kazalcem enkrat pritisnite škrlatni gumb na vrhu.
Usually, Humira is used with methotrexate.
Zdravilo Humira ponavadi uporabljamo z metotreksatom.
In patients not given concomitant methotrexate, the incidence was 25.6% (22/86) compared to 5.9% (5/85) when adalimumab was used as add-on to methotrexate.
Pri bolnikih, ki sočasno niso dobivali metotreksata, je bila incidenca 25,6 % (22/86) bolnikov, pri tistih, ki so adalimumab uporabljali kot dodatek metotreksatu, pa 5,9 % (5/85) bolnikov.